Vanderbilt Ingram Cancer Center

For more VICC news, visit their website »

May 8, 2017

VICC limited submission opportunity: V Foundation Immunology or Immunotherapy Award

The Vanderbilt-Ingram Cancer Center (VICC) has been invited to participate in The V Foundation 2017 Pediatric Cancer Research–Immunology or Immunotherapy Award.

By VUMC News and Communications
May 4, 2017

Lovly elected to American Society for Clinical Investigation

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt, has been elected to The American Society for Clinical Investigation (ASCI).

By VUMC News and Communications
April 27, 2017

Abramson to lead new Department of Radiology innovation program

Richard Abramson, M.D., will engage in creative program development as the Department of Radiology’s first Vice Chair for Innovation.

By Doug Campbell
April 27, 2017

VICC Annual Scientific Retreat slated for May 4

Leading cancer investigators from several prominent universities and laboratories will headline the 2017 Vanderbilt-Ingram Cancer Center Annual Scientific Retreat, to be held Thursday, May 4.

By VUMC News and Communications
Christine Lovly
April 24, 2017

Vanderbilt’s Christine Lovly elected to American Society for Clinical Investigation

By VUMC News and Communications
April 20, 2017

VICC Annual Scientific Retreat slated for May 4

Leading cancer investigators from several prominent universities and laboratories will headline the 2017 Vanderbilt-Ingram Cancer Center (VICC) Annual Scientific Retreat May 4.

By VUMC News and Communications
April 20, 2017

Vanderbilt’s W. Kimryn Rathmell named to ASCI leadership post

W. Kimryn Rathmell, director of the Division of Hematology/Oncology at Vanderbilt University Medical Center, has been named vice president of The American Society for Clinical Investigation.
By VUMC News and Communications
April 20, 2017

Study examines new breast cancer drug combination

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.
By VUMC News and Communications
April 13, 2017

Musician, physician collaborate to create message of hope on film

Nashville musician and producer Jesse Boyce compares the anxiety he felt just before receiving palliative radiation therapy to the jitters he often experienced before going on stage. The instant treatment began — and as the first note rang out — his anxiety was replaced by a sense of peace and determination.
By Jill Clendening
April 6, 2017

Vanderbilt’s Pietenpol joins Sledge as a Chief Scientific Advisor for Susan G. Komen

Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center (VUMC) and director of Vanderbilt-Ingram Cancer Center (VICC), has been named a Chief Scientific Advisor (CSA) for the nonprofit breast cancer organization Susan G. Komen.
By VUMC News and Communications
April 3, 2017

Vanderbilt investigator lands Stand Up To Cancer grant for “smart” nanoparticles cancer research

John Wilson, Ph.D., assistant professor of Chemical and Biomolecular Engineering and of Biomedical Engineering at Vanderbilt University, has received an Innovative Research Grant from Stand Up To Cancer (SU2C). Wilson is among 10 early-career scientists to receive the grant awards focused on immuno-oncology.
April 3, 2017

Funding opportunity: American Cancer Society-Institutional Research Grant

Applications are being sought for funding by the American Cancer Society‐Institutional Research Grant program. These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have external grant support.
By VUMC News and Communications
March 30, 2017

Horn to lead lung cancer combination therapy trial

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer.
By VUMC News and Communications
1 … 28 29 30 31 32 … 55